Sunrise Medical
This article was originally published in The Gray Sheet
Executive Summary
Gaining liquid oxygen products and a "demand oxygen delivery" device through the acquisition of Pierce, Florida-based Pulsair, Inc. The demand oxygen delivery device "reduces waste and cost by limiting delivery of oxygen to the inhalation segment of the breathing cycle," Sunrise claims. Pulsair, which had 1993 sales of about $7 mil., will operate as a unit of Sunrise's DeVilbiss respiratory products division, which makes nebulizers, concentrators and sleep apnea products. Pulsair products will enable DeVilbiss "to address the home respiratory market with the full-range of oxygen therapy modalities for patients with chronic obstructive lung disease," Sunrise Chairman and CEO Richard Chandler stated in a Jan. 24 press release. Pulsair manufacturing operations will remain at the Florida facility
You may also be interested in...
Prestige Expands UK Eye Care Range In Response To Consumer Demand
A “great consumer response” to TheraTears in the UK leads Prestige Consumer Healthcare to add TheraTears 5-in-1 Irritation and Redness eye drops to the range.
Who’s Hired? Hikma Recruits New US Generics President
A flurry of top level recruitments made headlines in the past weeks, with the likes of Hikma, Lupin, and Viatris announcing new hires while focusing on their targets for the year.
Organon And Henlius Complete Phase III For Denosumab
Having earlier this year reported positive Phase I data for their partnered denosumab biosimilar candidate, Organon and Shanghai Henlius Biotech have now announced that their HLX14 version has met primary endpoints in a Phase III study.